COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first reported as pneumonia in December 2019 in Wuhan, China. Since then, it has been spreading rapidly and WHO has declared it a pandemic on March 11, 2020 [1]. As of October, COVID-19 had affected about 8,029,217 cases worldwide and 111,802 cases in Nepal alone. Cutaneous manifestations have been reported in 20% of COVID-19 patients [2]. We report a case of erythema multiforme-like lesions in a young patient who was likely a case of a COVID-19 infection. Figure 1: Multiple erythema multiforme-like lesions over the dorsum of the bilateral feet, ankles and, distal legs.
Cutis verticis gyrata (CVG) is a rare condition of the scalp characterized by convoluted folds and furrows produced by the excessive growth of the skin of the scalp and resembling the cerebral gyri. CVG can be identified as primary—essential or nonessential—or secondary. Herein, we report the case of a 20-year-old female with primary essential CVG, who presented herself with thickened and convoluted skin folds over the vertex and parietal region of the scalp persistent for one year prior without other symptoms. CVG is a rare congenital or acquired disease distinguished by redundancy of the scalp skin that resembles the cerebral gyri. The management of primary essential CVG can be symptomatic or surgical depending on the patient’s aesthetic expectations.
Introduction: Melasma is the most common cause of facial melanosis and one of the most common diseases presenting to the Dermatology department. It can lead to psychological and emotional distress for the patients and can hamper their quality of life. So, this study was done to assess the quality of life among patients with melasma so that the need for couseling of these patients could be assessed along with medical treatment. Materials and Methods: This was a hospital based cross sectional study with 205 clinically diagnosed cases of melasma during the study period of one year. Melasma area severity index (MASI) score was recorded for each patient. Melasma quality of life was evaluated using the Melasma related Quality of Life (MELASQOL) score. MASI score and MELASQOL score were correlated using the Chi square test and socio-demographic details were also recorded. Results: The mean MASI score in our study was 14.39 and the mean MELASQOL score was 34.98. The correlation of the MASI score with the MELASQOL score was found to be statistically significant (p value = 0.000). Conclusion: MELASQOL score can be used to assess the quality of life in patients with melasma and the impairment in quality of life depends upon the MASI score.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.